SG11201709573YA - Specific modification of antibody with igg-binding peptide - Google Patents
Specific modification of antibody with igg-binding peptideInfo
- Publication number
- SG11201709573YA SG11201709573YA SG11201709573YA SG11201709573YA SG11201709573YA SG 11201709573Y A SG11201709573Y A SG 11201709573YA SG 11201709573Y A SG11201709573Y A SG 11201709573YA SG 11201709573Y A SG11201709573Y A SG 11201709573YA SG 11201709573Y A SG11201709573Y A SG 11201709573YA
- Authority
- SG
- Singapore
- Prior art keywords
- igg
- antibody
- binding peptide
- specific modification
- modification
- Prior art date
Links
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015103153 | 2015-05-20 | ||
| PCT/JP2016/065061 WO2016186206A1 (en) | 2015-05-20 | 2016-05-20 | SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201709573YA true SG11201709573YA (en) | 2017-12-28 |
Family
ID=57320461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201709573YA SG11201709573YA (en) | 2015-05-20 | 2016-05-20 | Specific modification of antibody with igg-binding peptide |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10227383B2 (en) |
| EP (1) | EP3299383A4 (en) |
| JP (2) | JP6872181B2 (en) |
| KR (1) | KR102651537B1 (en) |
| CN (1) | CN107614514B (en) |
| CA (1) | CA2985985A1 (en) |
| SG (1) | SG11201709573YA (en) |
| WO (1) | WO2016186206A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810923YA (en) * | 2016-06-13 | 2019-01-30 | Univ Kagoshima | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE |
| CN109790202B (en) | 2016-09-30 | 2022-09-13 | 富士胶片株式会社 | Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody drug complex and pharmaceutical preparation |
| WO2018092867A1 (en) * | 2016-11-18 | 2018-05-24 | 国立大学法人鹿児島大学 | Solid support containing igg-binding peptide, and method for separating igg |
| KR20200002858A (en) * | 2017-04-28 | 2020-01-08 | 아지노모토 가부시키가이샤 | Compounds having affinity, cleavable moieties and reactive groups for soluble proteins or salts thereof |
| WO2018230257A1 (en) * | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | IgG-BINDING PEPTIDE, AND SPECIFIC MODIFICATION OF ANTIBODY WITH SAID PEPTIDE |
| TW202003556A (en) | 2018-04-16 | 2020-01-16 | 日商日本醫事物理股份有限公司 | Modified antibody and radioactive metal-labelled antibody |
| WO2019240287A1 (en) | 2018-06-14 | 2019-12-19 | 味の素株式会社 | Compound comprising substance having affinity for antibody, cleavage site and reactive group, or salt thereof |
| EP3811978A4 (en) * | 2018-06-14 | 2022-03-16 | Ajinomoto Co., Inc. | Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group |
| JP2020019723A (en) * | 2018-07-30 | 2020-02-06 | 国立大学法人 鹿児島大学 | Complex of anti-CD70 antibody and IgG binding peptide |
| US20210380637A1 (en) * | 2018-10-10 | 2021-12-09 | Kagoshima University | SOLID-PHASE CARRIER INCLUDING IgG-BINDING PEPTIDE, AND IgG SEPERATION METHOD |
| WO2020090979A1 (en) | 2018-10-31 | 2020-05-07 | 味の素株式会社 | Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof |
| US20220072147A1 (en) * | 2019-01-23 | 2022-03-10 | AbTis Co., Ltd. | Compound for preparation of antibody-payload conjugate and use thereof |
| KR102563319B1 (en) * | 2019-03-08 | 2023-08-03 | 앱티스 주식회사 | Site-specific antibody conjugation, and antibody-drug conjugate as its embodiment |
| CN114585393A (en) | 2019-10-18 | 2022-06-03 | 日本医事物理股份有限公司 | RI-labeled humanized antibodies |
| US20230248854A1 (en) * | 2019-10-18 | 2023-08-10 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive metal-labeled antibody |
| JPWO2021080008A1 (en) | 2019-10-24 | 2021-04-29 | ||
| US20230210967A1 (en) | 2020-04-23 | 2023-07-06 | Brightpath Biotherapeutics Co., Ltd. | Improved peptide vaccine |
| TW202216174A (en) | 2020-06-30 | 2022-05-01 | 日商蓋亞生物製藥有限公司 | Method for stabilizing binding of antibody to NK cell and use thereof |
| WO2022080385A1 (en) * | 2020-10-13 | 2022-04-21 | 国立大学法人京都大学 | Peptide, and modification of antibody with peptide |
| US20230390425A1 (en) | 2020-10-16 | 2023-12-07 | Nihon Medi-Physics Co., Ltd. | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
| CA3197961A1 (en) | 2020-11-09 | 2022-05-12 | Kagoshima University | Peptide crosslinking agent and crosslinked peptide which is crosslinked using said crosslinking agent |
| JP2021049375A (en) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | Game machine |
| EP4276855A1 (en) | 2021-01-08 | 2023-11-15 | Nihon Medi-Physics Co., Ltd. | Production method for ac-225 solution and production method for medicine using ac-225 solution |
| AU2022208654A1 (en) | 2021-01-18 | 2023-08-03 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody produced using same |
| WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
| WO2022178753A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising targeting moiety binding fragments and uses thereof |
| CN116964076A (en) | 2021-03-11 | 2023-10-27 | 味之素株式会社 | Compounds or salts thereof, and antibodies derived therefrom |
| WO2022196675A1 (en) | 2021-03-16 | 2022-09-22 | 味の素株式会社 | Complex or salt thereof, and method for manufacturing same |
| AU2022250323A1 (en) | 2021-03-31 | 2023-11-09 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
| JPWO2022224980A1 (en) | 2021-04-20 | 2022-10-27 | ||
| WO2022225007A1 (en) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | Radioactive antitumor agent |
| CN117377696A (en) | 2021-04-21 | 2024-01-09 | 日本医事物理股份有限公司 | Humanized antibodies labeled with beta-emitting nuclides |
| CA3222359A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| TW202325343A (en) | 2021-08-31 | 2023-07-01 | 日商日本醫事物理股份有限公司 | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
| CA3231257A1 (en) | 2021-09-08 | 2023-03-16 | Yuji Ito | Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody |
| WO2024096564A1 (en) * | 2022-11-01 | 2024-05-10 | 앱티스 주식회사 | Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751286A (en) * | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
| FR2604092B1 (en) | 1986-09-19 | 1990-04-13 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
| US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
| US7074405B1 (en) | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| WO2003101495A1 (en) | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
| MX2011000647A (en) * | 2008-07-18 | 2011-09-29 | Trinity Therapeutics Inc | Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome. |
| CN102892885B (en) * | 2010-05-24 | 2015-08-19 | 国立大学法人鹿儿岛大学 | IgA binding peptide and utilize its purifying of IgA |
| US8916689B2 (en) | 2010-09-06 | 2014-12-23 | GE Health Bio-Sciences AB | Method for labeling of compounds |
| CN103890174B (en) * | 2011-08-24 | 2015-12-23 | 大塚化学株式会社 | IgG binding peptide and utilize it to detect and the method for IgG purification |
| SG11201810923YA (en) * | 2016-06-13 | 2019-01-30 | Univ Kagoshima | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE |
| US20210380637A1 (en) * | 2018-10-10 | 2021-12-09 | Kagoshima University | SOLID-PHASE CARRIER INCLUDING IgG-BINDING PEPTIDE, AND IgG SEPERATION METHOD |
-
2016
- 2016-05-20 SG SG11201709573YA patent/SG11201709573YA/en unknown
- 2016-05-20 US US15/575,138 patent/US10227383B2/en active Active
- 2016-05-20 KR KR1020177034487A patent/KR102651537B1/en active IP Right Grant
- 2016-05-20 CA CA2985985A patent/CA2985985A1/en active Pending
- 2016-05-20 EP EP16796599.5A patent/EP3299383A4/en active Pending
- 2016-05-20 CN CN201680027878.1A patent/CN107614514B/en active Active
- 2016-05-20 WO PCT/JP2016/065061 patent/WO2016186206A1/en active Application Filing
- 2016-05-20 JP JP2017519419A patent/JP6872181B2/en active Active
-
2020
- 2020-09-16 JP JP2020155354A patent/JP7076152B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7076152B2 (en) | 2022-05-27 |
| WO2016186206A1 (en) | 2016-11-24 |
| JP2020203940A (en) | 2020-12-24 |
| EP3299383A4 (en) | 2019-01-23 |
| EP3299383A1 (en) | 2018-03-28 |
| CA2985985A1 (en) | 2016-11-24 |
| US10227383B2 (en) | 2019-03-12 |
| KR102651537B1 (en) | 2024-03-25 |
| JP6872181B2 (en) | 2021-05-19 |
| CN107614514B (en) | 2022-03-01 |
| KR20180002734A (en) | 2018-01-08 |
| CN107614514A (en) | 2018-01-19 |
| US20180141976A1 (en) | 2018-05-24 |
| JPWO2016186206A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201709573YA (en) | Specific modification of antibody with igg-binding peptide | |
| IL283321A (en) | Anti-muc16 antibodies and uses thereof | |
| IL285375A (en) | Il-8-binding antibodies and uses thereof | |
| HK1254861A1 (en) | Anti-lag3 antibodies and uses thereof | |
| IL264159A (en) | Anti-tim-3 antibodies | |
| HK1250238A1 (en) | Anti-angptl8 antibodies and uses thereof | |
| HK1256381A1 (en) | Anti-pacap antibodies and uses thereof | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| GB201603291D0 (en) | Antibodies | |
| PT3292154T (en) | Anti-human-her3 antibodies and uses thereof | |
| IL258924A (en) | Humanized anti-dkk2 antibody and uses thereof | |
| IL264262A (en) | Anti-il-22r antibodies | |
| GB201616699D0 (en) | Antibodies | |
| HK1254240A1 (en) | Anti-hypusine antibodies and uses thereof | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies |